Reinforcement Learning-Enhanced Dual-View GAT-Based Multi-Task Learning for Non-Coding RNA-Disease Association Prediction

Read full text Summarise with VIRAT
Authors: N G Keichin, Yulian Ding, Yanjie Wei, Yajun Liu, Yi Pan
Cited by: 0
References: 46

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Non-coding RNAs (ncRNAs), particularly long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are important regulators of gene expression and are closely involved in disease pathogenesis. Therefore, identifying ncRNA-disease associations is essential for clarifying disease mechanisms. Because lncRNAs and miRNAs frequently regulate each other in cells, predicting miRNA-disease associations (MDA) and lncRNA-disease associations (LDA) is inherently interconnected. However, many existing computational approaches still treat these tasks as independent problems, which limits their ability to capture cross-task biological signals. In addition, most models use fixed hyperparameters, which may be suboptimal as training dynamics and data characteristics change. To address these issues, we propose RL-DMGLMD (Reinforcement Learning-enhanced Dual-view Multi-task Graph learning for LncRNA-MiRNA-Disease association prediction). RL-DMGLMD contains three key components: (1) a Soft Actor-Critic (SAC) controller that adaptively tunes hyperparameters during training by monitoring loss, validation performance, and gradient information; (2) a unified multi-task framework that jointly predicts LDA, MDA, and lncRNA-miRNA interactions (LMI) using shared encoders with task-specific decoders to enable knowledge transfer; and (3) a dual-view multi-head Graph Attention Network (GAT) that learns from both heterogeneous interaction graphs and attribute graphs to capture relation-specific importance. RL-DMGLMD achieves AUROC values of 0.9900 / 0.9872 / 0.9867 on Dataset 1 and 0.9946 / 0.9903 / 0.9954 on Dataset 2 for LDA, MDA, and LMI, respectively. These results outperform state-of-the-art baselines and support RL-DMGLMD as a practical tool for biomarker discovery and therapeutic target prioritization.

Fields of Study & Subjects

Cancer-related molecular mechanisms research MicroRNA in disease regulation Bioinformatics and Genomic Networks

Publication details

Journal / source
IEEE Journal of Biomedical and Health Informatics
Volume
30
Issue
10
Pages
8597–8609
Publication date
27 March 2026
Language
EN